Myriad Genetics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all.

[Myriad Genetics @myriadgenetics]

𝐈𝐬 𝐌𝐑𝐃 𝐛𝐞𝐜𝐨𝐦𝐢𝐧𝐠 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐭𝐨 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭?

As precision oncology advances, researchers and developers now detect treatment response 𝐞𝐚𝐫𝐥𝐢𝐞𝐫, 𝐝𝐞𝐞𝐩𝐞𝐫, 𝐚𝐧𝐝 𝐦𝐨𝐫𝐞 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞𝐥𝐲, reshaping how teams develop and evaluate therapies.

In a new episode of @FiercePharma's The Top Line, Dale Muzzey, Chief Scientific Officer, and Lou Welebob, Senior Vice President of Biopharma and Companion Diagnostics, explore how 𝐭𝐮𝐦𝐨𝐫-𝐢𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 (𝐌𝐑𝐃) 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 is emerging as a powerful tool in clinical trials and companion diagnostics, helping biopharma teams:

🔵 Detect response earlier in the treatment journey
🔵 Improve patient selection and trial design
🔵 Generate deeper, quantitative insights into tumor dynamics over time
🔵 Make more informed decisions to potentially accelerate development

When teams integrate diagnostics earlier in development, they mitigate risk, improve efficiency, and ultimately drive better outcomes for patients.

🎧Listen to the full discussion to learn how MRD is shaping the future of #oncology drug development and #companiondiagnostics.

👉https://t.co/uTQYseEbf4

#MRD #precisionmedicine #biopharma #ctDNA #drugdevelopment #clinicaltrials

[Myriad Genetics @myriadgenetics]

Active surveillance for prostate cancer continues to evolve, and we're thrilled to see Prolaris® + AI highlighted by The Active Surveillor for its utility in helping physicians make more informed decisions around #patientcare: https://t.co/vt6HgEKoVi

#prostatecancer #urology

[Myriad Genetics @myriadgenetics]

Thank you @WomensHealthMag for sharing this essay & the importance of #genetictesting 💙.

👉Learn more: https://t.co/cK7uct2Sb9

[Women's Health @WomensHealthMag]

How Genetic Testing Saved Jackie Tohn’s Life https://t.co/EtgtUz5mLc

[Myriad Genetics @myriadgenetics]

Colorectal Cancer (CRC) care doesn't end in the OR. With the MyRisk® Hereditary Cancer Test you receive clear, guideline-aligned recommendations to help inform lifelong CRC care - for patients and their families: surveillance intensity, second cancer screening, specialty referrals, and family risk assessment.₁,₆₋₈

In addition, Myriad helps make testing accessible and affordable by offering a financial assistance program for eligible patients, consultations with board certified genetic counselors at no additional cost, and access programs where most patients pay nothing out of pocket.₁₁

One decision at diagnosis can shape a lifetime of care for your patient and their family.

Order the MyRisk test and view full references (1,6-8,11): https://t.co/lndjvxROnT.

#genomictesting #cancercarecontinuum #hereditarycancer #geneticinsights #coloncancer

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 9, 2026. To view the most recent and complete version of the guideline, go online to https://t.co/SaLUDQ2wEm. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
6. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148-177.
7. Herzig DO, Buie WD, Weiser MR, et al. Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome. Dis Colon Rectum. 2017;60(2):137-143.
8. Poylin VY, Shaffer VO, Felder SI, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes. Dis Colon Rectum. 2024;67(2):213-227.
11. Data on File at Myriad Genetics, Inc. Based on a review of 12 months of past claim data for major insurance carriers across the US, the majority of patients face no out-of-pocket costs for their MyRisk test. Last updated 2024.

[Myriad Genetics @myriadgenetics]

Move toward approaches that bring together clinical insight, genomics, and AI to deliver a more complete understanding of disease biology.

Start testing with the Prolaris® + AI Test today: https://t.co/SdVw1KmmYb

#Urology #ProstateCancer #GeneticTesting #GeneticInisghts

[Myriad Genetics @myriadgenetics]

We're honored to be recognized on the 2026 @Forbes list of America's Best Employers for New Grads, our second time earning this distinction. 🎊

At Myriad Genetics, we know that early career professionals play a vital role in advancing our mission. From meaningful growth opportunities to innovative internships, we're committed to supporting the next generation of talent as they develop impactful careers.

👉View current opportunities at Myriad: https://t.co/QdUEsV2Gk7

👉See the full list of honorees: https://t.co/8E8b0G5a3f

#teamMyriad

[Myriad Genetics @myriadgenetics]

🎊Excited to see Prolaris® + AI featured on @GenomeWeb!

If you haven't yet, be sure to see the full article and learn how we're advancing precision medicine for #prostatecancer patients and their clinicians: https://t.co/NImDL1WuY9.

#innovation #healthcareprofessionals

[Myriad Genetics @myriadgenetics]

Six years ago, Myriad Genetics® proudly rolled out AMPLIFY® technology, a game changer in prenatal cell-free DNA screening. Back then, the introduction of AMPLIFY technology into the Prequel® Prenatal screen meant that 99.9% of patients taking the screen at 10 weeks' gestation would get a result the first time.₁,₂

In 2024, Myriad made the Prequel screen available at eight weeks, with comparable results on the very first draw.₃,₄ Innovations like these have long made Myriad Genetics a pioneer in the #prenatal space, consistently delivering important genetic insights to healthcare providers and patients alike. And this is just the beginning!

1. Hancock S, Ben-Shachar R, Adusei C, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430. doi:10.1002/uog.21904. 
2. Muzzey D, Goldberg JD, Haverty C. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2019;40(3):333-341. doi:10.1002/pd.56033.
3. Eight weeks failure rate is 0.2%
4. Dugoff, L., et al. (2025, January 30). Fetal fraction amplification enables accurate prenatal cell-free DNA screening at 8 weeks gestation. Plenary session presented at the Society for Maternal-Fetal Medicine Conference, Denver, CO.
5. As of June 2026

[Myriad Genetics @myriadgenetics]

Hereditary cancer genetic findings can directly influence extent of resection, anastomotic strategy, and early surveillance planning.₁,₆

The MyRisk® Hereditary Cancer Test is built for the clinical timeline of colorectal cancer (CRC) care. It delivers results typically within 14 days - or as fast as 7 days with STAT priority ordering for eligible patients* - plus guideline-aligned recommendations linking positive results to operative choices.

Don't risk missing the window to inform index surgery.

👉Learn more and view full references: https://t.co/lndjvxROnT

#germlinetesting #CRCsurgery #oncology #hereditarycancer #geneticinsights #STAT

*patients with government insurances, including but not limited to Tricare Prime, Medicaid, Indian Health Services, VA, etc. may not be eligible for MyRisk STAT

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 9, 2026. To view the most recent and complete version of the guideline, go online to https://t.co/SaLUDQ2wEm. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
6. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148-177.

[Myriad Genetics @myriadgenetics]

We're honored to be named a 2026 Women Tech Council Shatter List recipient for the second year in a row!

The Shatter List recognizes organizations helping shape the future of Utah's innovation economy through mentorship, workforce development, #leadership engagement, industry collaboration, and investment in the next generation of talent. This honor reflects our commitment to fostering an environment where people can grow, lead, and make an impact while contributing to a strong culture of #innovation, both within Myriad and throughout the communities we serve.

Thank you to the Women Tech Council and to our teammates, whose expertise, leadership, and dedication make Myriad a place where we continue to make an impact every day.

👉See the full list of 2026 recipients: https://t.co/YSZQkxTI24.

[Myriad Genetics @myriadgenetics]

We're excited to showcase the new 𝐏𝐫𝐨𝐥𝐚𝐫𝐢𝐬®+ 𝐀𝐈 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐓𝐞𝐬𝐭 on our upcoming educational #webinar!

Be among the first to hear how this enhancement supports deeper insights to help guide active surveillance decisions and personalized treatment planning.

𝐏𝐫𝐨𝐥𝐚𝐫𝐢𝐬+ 𝐀𝐈: 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐄𝐫𝐚 𝐨𝐟 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬
🔵Date & Time: Thursday, June 18, 2026 | 5:00 PM - 6:00 PM ET
🔵Guest Speakers: Kirk Wojno, MD and Stephen Freedland, MD

👉Register 𝐭𝐨𝐝𝐚𝐲: https://t.co/xRglVvb7T8

#prostatecancer #geneticinsights #urology

[Myriad Genetics @myriadgenetics]

𝐓𝐡𝐞 𝐨𝐧𝐥𝐲 𝐭𝐞𝐬𝐭 𝐛𝐮𝐢𝐥𝐭 𝐟𝐨𝐫 𝐚𝐜𝐭𝐢𝐯𝐞 𝐬𝐮𝐫𝐯𝐞𝐢𝐥𝐥𝐚𝐧𝐜𝐞 – 𝐍𝐨𝐰 𝐞𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐛𝐲 𝐀𝐈

Start tailoring active surveillance management today: https://t.co/k4382m7yQS

#Urology #ProstateCancer #GeneticTesting #GeneticInisghts

[Myriad Genetics @myriadgenetics]

Thrilled to see Dr. @AliabadiMD's recent appearance on @KTLA, where she emphasized the importance of a proactive approach to women's health - from understanding #breastcancer risk and fertility to advocating for comprehensive preventive care.

👉See the video: https://t.co/YfjVrOzxlN.

At Myriad, we are committed to advancing and supporting conversations that empower women to make informed healthcare decisions.

#cancerrisk #hereditarycancer

[Myriad Genetics @myriadgenetics]

Traditional tumor-based screening (MSI/IHC) is essential for Lynch syndrome screening and immunotherapy decisions - but it only covers 5 of the 24 CRC-linked genes, leading to over 69% of hereditary syndromes in colorectal cancer (CRC) that go missed.₁,₅

Germline testing with the MyRisk® Hereditary Cancer Test goes further: it covers all Lynch syndrome genes and others like APC, MUTYH, POLE, PTEN, and TP53 to inform CRC surgical planning, surveillance, and family care.₁,₆₋₈

Don't let critical risk go undetected. Go beyond tumor testing.

Learn more and view full references (1, 6-8): https://t.co/COGyD4i4S5

#germlinetesting #CRCsurgery #oncology #hereditarycancer #geneticinsights

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 9, 2026. To view the most recent and complete version of the guideline, go online to https://t.co/SaLUDQ2wEm. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
5. Yurgelun MB, Kulke MH, Fuchs CS, et al. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017;35(10):1086-1095.
6. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022;65(2):148-177.
7. Herzig DO, Buie WD, Weiser MR, et al. Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome. Dis Colon Rectum. 2017;60(2):137-143.
8. Poylin VY, Shaffer VO, Felder SI, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes. Dis Colon Rectum. 2024;67(2):213-227.

[Myriad Genetics @myriadgenetics]

Today we announced the appointment of Raj Jampa as chief technology officer (CTO), effective June 1, 2026.

👉Read more: https://t.co/Kek0TQLzqm

[Myriad Genetics @myriadgenetics]

🎉Excited to share that our Health Management Marketing team has been recognized for four honors in the 43rd Annual Healthcare Advertising Awards! The recognized work spans multiple brands and campaigns and reflects our commitment to connecting patients and clinicians with information that can help guide important healthcare decisions.

Congratulations to the talented teammates and partners involved in these impactful campaigns, whose creativity, expertise, and dedication supports our mission of advancing health and well-being for all.

👉See the full list: https://t.co/IgGIL6qYyA

#teamMyriad #healthcareprofessionals #awards

[Myriad Genetics @myriadgenetics]

#ASCO26 attendees: Join us this morning for our Industry Expert Theater: Ultra-Sensitive Molecular Residual Disease Detection with Myriad's Precise MRD™ Test

🔵Sunday, May 31
🔵9:30 AM - 10:30 AM CT
🔵Exhibit Hall - Industry Expert Theater 1
🔵Presenter: Dale Muzzy, PhD, Chief Scientific Officer, Myriad Genetics

After the session, stop by booth # 25081 to continue the conversation and explore Myriad's latest research, clinical data, and product roadmap shaping the future of precision #oncology.

#myriadoncology

*Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

[Myriad Genetics @myriadgenetics]

Don't miss our #ASCO26 Industry Expert Theater tomorrow at 9:30 AM.

Ultra-Sensitive Molecular Residual Disease Detection with Myriad's Precise MRD™ Test
Presenter: Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics

This session will cover assay technical details and emerging clinical evidence across multiple solid tumors, including breast and colorectal cancers, and explore the role of highly sensitive molecular residual disease (MRD) detection across the cancer care continuum.

Stop by booth # 25081 to explore our latest research and expanding body of data in molecular disease detection: https://t.co/qBhRRHSqEu

#oncology #myriadoncology #geneticinsights

*Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

[Myriad Genetics @myriadgenetics]

𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 𝐩𝐫𝐨𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐣𝐮𝐬𝐭 𝐞𝐧𝐭𝐞𝐫𝐞𝐝 𝐚 𝐧𝐞𝐰 𝐞𝐫𝐚.

Get started with the Prolaris® + AI Test today: https://t.co/ZXwdICowg9

#Urology #ProstateCancer #GeneticTesting #GeneticInisghts

[Myriad Genetics @myriadgenetics]

Today we announced we will share data demonstrating the utility of Myriad's Precise MRD™ (molecular residual disease) test across diverse cancer types.

👉See more: https://t.co/2CZnQGXdq7

@ASCO